White Paper

Manufacturing Challenges With High Concentration Biologics

Source: Cytiva

Monoclonal antibody (mAb) therapies possess a unique blend of specificity and versatility, making them a strong candidate for treating a range of diseases, such as autoimmune disorders and cancers. As the scope of diseases targetable by mAbs, recombinant proteins (rPros), and antibody-drug conjugates (ADCs) expands, opportunities arise to address challenges in administration methods, enhancing patient experience and lessening the burden on healthcare providers.

Over the past decade, rapid advances have been made in enabling subcutaneous delivery methods as opposed to traditional intravenous (IV) infusion. The proliferation of drugs formulated for subcutaneous (Sub-C) injection underscores the manufacturing challenges associated with higher concentrations of active ingredients and formulation components. Manufacturing operations directly impacted by these higher-concentration formulations span from ultrafiltration to sterile filtration, filling, mixing, and storage. Effective solutions must uphold quality, optimize process yields and product recovery, and ideally, be adaptable to existing manufacturing platforms. This white paper explores key process operations, identifies challenges in manufacturing high-concentration biologics, and offers considerations for process optimization.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development